[go: up one dir, main page]

AU1253002A - Imidazo-triazine derivatives as ligands for gaba receptors - Google Patents

Imidazo-triazine derivatives as ligands for gaba receptors

Info

Publication number
AU1253002A
AU1253002A AU1253002A AU1253002A AU1253002A AU 1253002 A AU1253002 A AU 1253002A AU 1253002 A AU1253002 A AU 1253002A AU 1253002 A AU1253002 A AU 1253002A AU 1253002 A AU1253002 A AU 1253002A
Authority
AU
Australia
Prior art keywords
triazine derivatives
ligands
imidazo
sub
gaba receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU1253002A
Inventor
Michela Bettati
Peter Blurton
William Robert Carling
Mark Stuart Chambers
David James Hallett
Andrew Jennings
Richard Thomas Lewis
Michael Geoffrey Neil Russell
Leslie Joseph Street
Helen Jane Szekeres
Monique Bodil Van Niel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0027562A external-priority patent/GB0027562D0/en
Priority claimed from GBGB0117277.4A external-priority patent/GB0117277D0/en
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU1253002A publication Critical patent/AU1253002A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a -NH- linkage, being selective ligands for GABA<SUB>A </SUB>receptors, in particular having good affinity for the alpha2 and/or alpha3 and/or alpha5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
AU1253002A 2000-11-10 2001-11-08 Imidazo-triazine derivatives as ligands for gaba receptors Pending AU1253002A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0027562A GB0027562D0 (en) 2000-11-10 2000-11-10 Therapeutic agents
GBGB0117277.4A GB0117277D0 (en) 2001-07-16 2001-07-16 Therapeutic agents
PCT/GB2001/004948 WO2002038568A1 (en) 2000-11-10 2001-11-08 Imidazo-triazine derivatives as ligands for gaba receptors

Publications (1)

Publication Number Publication Date
AU1253002A true AU1253002A (en) 2002-05-21

Family

ID=26245271

Family Applications (2)

Application Number Title Priority Date Filing Date
AU1253002A Pending AU1253002A (en) 2000-11-10 2001-11-08 Imidazo-triazine derivatives as ligands for gaba receptors
AU2002212530A Ceased AU2002212530B2 (en) 2000-11-10 2001-11-08 Imidazo-triazine derivatives as ligands for GABA receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002212530A Ceased AU2002212530B2 (en) 2000-11-10 2001-11-08 Imidazo-triazine derivatives as ligands for GABA receptors

Country Status (9)

Country Link
US (1) US6936608B2 (en)
EP (1) EP1343788B1 (en)
JP (1) JP4302980B2 (en)
AT (1) ATE310740T1 (en)
AU (2) AU1253002A (en)
CA (1) CA2427779A1 (en)
DE (1) DE60115282T2 (en)
ES (1) ES2251518T3 (en)
WO (1) WO2002038568A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0212048D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
ATE420867T1 (en) * 2002-08-13 2009-01-15 Merck Sharp & Dohme PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
AU2003278377A1 (en) 2002-11-06 2004-06-07 Merck Sharp And Dohme Limited Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic
US7365174B2 (en) 2003-08-22 2008-04-29 Meiji Seika Kaisha, Ltd. Azalide and azalactam derivatives and method for producing the same
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007073283A1 (en) 2005-12-20 2007-06-28 Astrazeneca Ab Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis
US7465795B2 (en) 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
KR20090064418A (en) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 Combination with 4-acylaminopyridine derivatives
RS52677B (en) 2006-11-22 2013-06-28 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110082147A1 (en) * 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
CN102030770B (en) * 2009-09-25 2012-10-31 北京大学 A kind of preparation method of aromatic borate ester compound
EP2468726B1 (en) * 2010-12-06 2013-08-28 Siena Biotech S.p.A. Compound for the treatment of tumours and tumour metastases
CN102898315B (en) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 Method for preparing 3-ethynyl-4-fluoroaniline
UA112028C2 (en) 2012-12-14 2016-07-11 Пфайзер Лімітед IMIDAZOPYRIDASINE DERIVATIVES AS HAMBA-RECEPTOR MODULATORS
CN104177304A (en) * 2013-05-28 2014-12-03 海洋王照明科技股份有限公司 Bipolar blue light phosphorescent host material, preparation method and organic electroluminescent device thereof
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EA201691594A1 (en) 2014-02-13 2017-02-28 Инсайт Корпорейшн CYCLOPROPYLAMINES AS LSD1 INHIBITORS
CN111454188A (en) 2014-02-13 2020-07-28 因赛特公司 Cyclopropylamines as L SD1inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6491679B2 (en) 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Imidazopyridazine derivatives as modulators of GABA A receptor activity
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
EP3334709B1 (en) 2015-08-12 2024-12-11 Incyte Holdings Corporation Salts of an lsd1 inhibitor
UA125463C2 (en) 2016-01-27 2022-03-16 Універсітет Цюріх USE OF GABA<sub>A</sub> RECEPTOR MODULATORS FOR TREATMENT OF ITCH
CN110799267B (en) 2017-03-21 2023-05-26 密西西比州立大学 Unsymmetrical salt, CCC-NHC pincer metal complex and preparation method thereof
CA3096890A1 (en) * 2018-04-18 2019-10-24 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
AU2020371635A1 (en) * 2019-10-22 2022-06-09 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
CN116693555A (en) 2022-02-25 2023-09-05 上海赛默罗生物科技有限公司 Imidazopyridazine derivative, preparation method, pharmaceutical composition and application thereof
CN117069725A (en) 2022-05-10 2023-11-17 上海赛默罗生物科技有限公司 Imidazopyridazine substituted benzene ring derivative, preparation method, pharmaceutical composition and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1581125B1 (en) 1966-03-26 1970-08-27 Maierform Trust Reg Bow for displacement ships
US3422194A (en) * 1967-08-15 1969-01-14 Smithkline Corp The treatment of depression with imidazo(1,2-b)-as-triazines and compositions thereof
AU777961B2 (en) * 1999-06-22 2004-11-04 Neurosearch A/S Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
GB0117277D0 (en) * 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
US20040023964A1 (en) 2004-02-05
ES2251518T3 (en) 2006-05-01
JP2004513171A (en) 2004-04-30
DE60115282D1 (en) 2005-12-29
EP1343788A1 (en) 2003-09-17
EP1343788B1 (en) 2005-11-23
ATE310740T1 (en) 2005-12-15
CA2427779A1 (en) 2002-05-16
US6936608B2 (en) 2005-08-30
DE60115282T2 (en) 2006-08-10
WO2002038568A1 (en) 2002-05-16
AU2002212530B2 (en) 2006-08-17
JP4302980B2 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
AU1253002A (en) Imidazo-triazine derivatives as ligands for gaba receptors
GB0212048D0 (en) Therapeutic agents
DE60012044D1 (en) IMIDAZOPYRIDE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
GB0117277D0 (en) Therapeutic agents
IL157641A0 (en) Imidazo-pyrimidine derivatives as ligands for gaba receptors
ATE338758T1 (en) IMIDAZOPYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
DE60016566D1 (en) TRIAZOLOPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS
GB0212049D0 (en) Therapeutic agents
TW359670B (en) Process for producing quinazolin-4-one derivatives
PE20050482A1 (en) DIHYDROBENZOFURANIL ALKANAMIDE DERIVATIVES
IL123585A0 (en) Novel N-aminoalkylfluorene-carboxamides a new class of dopamine receptor subtype specific ligands
ATE253066T1 (en) IMIDAZOTRIAZINE DERIVATIVES AS GABA RECEPTOR LIGANDS
DE60325865D1 (en) PHENYLPYRIDAZINE DERIVATIVE AS LIGANDS FOR GABA RECEPTORS
DE69911374D1 (en) TRIAZOLOPIRIDAZINE DERIVATIVES AS GABA RECEPTOR LIGANDS
WO2000018767A3 (en) 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
ATE366726T1 (en) STEREOSELECTIVE SYNTHESIS OF CERTAIN TRIFLUOROMETHYL-SUBSTITUTED ALCOHOLS
JO2312B1 (en) Imidazo-pyrimidine derivative as ligands for gaba receptors
MY139258A (en) Carbamoyl-type benzofuran derivatives
HUP0001391A2 (en) 1-(isoquinolin-1-yl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
EP1325909A4 (en) Tricyclic indole compounds having affinity for serotonin receptor
WO2005063687A3 (en) New process for the synthesis of eneamide derivatives
DK1140919T3 (en) 1,4-Disubstituted cyclohexane derivatives for the treatment of depression